Markowitz Wayne 4
4 · Edwards Lifesciences Corp · Filed May 9, 2025
Insider Transaction Report
Form 4
Markowitz Wayne
GM & SVP, Surgical
Transactions
- Sale
Common Stock
2025-05-07$75.08/sh−268$20,121→ 9,299.192 total - Tax Payment
Common Stock
2025-05-07$74.92/sh−300$22,476→ 8,999.192 total - Award
Common Stock
2025-05-08+3,350→ 12,349.192 total - Award
Employee Stock Option (Right to Acquire)
2025-05-08+17,100→ 17,100 totalExercise: $74.63From: 2026-05-08Exp: 2032-05-07→ Common Stock (17,100 underlying) - Award
Performance Rights
2025-05-08+3,350→ 3,350 totalFrom: 2028-05-08→ Common Stock (3,350 underlying)
Footnotes (3)
- [F1]These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F2]These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F3]Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.